March 28, 2020
Wilson’s Disease Drugs

Wilson’s Disease Drugs Market | North America is the most significant market

The global Wilson’s disease drugs market was valued at US$ 372.5 Mn in 2016, and is expected to reach US$ 592.8 Mn by 2025 expanding at a CAGR of 5.19 % from 2017 to 2025.

Market Insights

Pharmaceutical manufacturers are currently focusing on addressing the abnormal metabolism of copper in order to prevent excessive deposition of copper in the liver and other organs. WTX101, also known as bis-choline tetrathiomolybdate developed by Wilson Therapeutics AB, has shown promising results in a phase 3 clinical trial for Wilson disease. It is the first novel copper protein binding agent with a unique mechanism of action. WTX101 has a high specificity for copper and forms copper protein complexes and provides an alternative mechanism for the transport of copper protein. Excessive levels of copper are reduced in the blood and liver cells and promote biliary excretion of copper. Gene therapy is also a feasible option to transport functional ATPB7 genes via gene vectors.

Access Sample Copy Of This Report:

Chelators are the first line of treatment for disease management of Wilson’s disease. They prevent the excessive deposition of copper in liver cells by expediting urine excretion of copper. Zinc is used in patients non-reactive to chelators therapy. It has less adverse events and used in long term therapy of Wilson’s disease.

The hepatic conditions are first diagnosed in patients suffering with Wilson’s disease due to large accumulation of copper in the liver cells causing an increase in aspartate aminotransferase and alanine aminotransferase. Neuropsychiatric symptoms are manifested in the later stages of the disease with patient showing symptoms of seizures, ataxia and tremors.

North America currently enjoys a leading position in Wilson’s drug treatment market due to the increasing prevalence of Wilson’s disease in the Caucasian population and the supportive regulatory environment provided by the USFDA for drugs used to treat Wilson’s disease. Recent technological advances in laboratory diagnostics in Asia Pacific have resulted in accurate diagnosis of patients with Wilson’s disease. Asia Pacific has a tremendous opportunity for its established generic market to manufacture drugs that are otherwise imported from western countries.

The pharmaceutical companies proactive in the treatment of Wilson’s disease are Kadmon Holdings, Inc., Valeant Pharmaceuticals International, Inc., Merck & Co., Noble Pharma Co., Ltd., Teva Pharmaceutical Industries Limited, Tsumura & Co., VHB Life Sciences, Inc. and Wilson Therapeutics AB.

Access Sample Copy Of This Report:

Key Market Movements:

  • Accurate diagnosis of symptoms has brought enormous patients suffering with Wilson’s disease in drug treatment regimen
  • Orphan disease status has acquired supportive regulatory milieu for the novel drug discovery and development of Wilson’s disease
  • Enormous opportunity for major pharma players to conduct clinical trials and establish R&D centers in developing nations with unmet medical needs

Leave a Reply

Your email address will not be published. Required fields are marked *